Journal of cardiac failure
Audio Summaries

Impact of empagliflozin on serum calcium and phosphate in heart failure

Aug 7, 2026

The authors aimed to investigate the prognostic associations of serum calcium and phosphate levels in heart failure patients and the impact of the SGLT2 inhibitor empagliflozin on these levels. They found that low serum calcium was associated with worse outcomes, but it did not significantly influence the efficacy of empagliflozin, which was shown to induce a minor increase in both serum calcium and phosphate levels over time. Overall, while low serum calcium may indicate poorer prognosis, it did not affect the treatment outcomes with empagliflozin.

Stepping it Up on Temporary Mechanical Circulatory Support - Mobilization and Prehabilitation of patients in ICU

Jul 28, 2026

This review investigates the implementation and efficacy of early mobilization and prehabilitation strategies for patients on temporary mechanical circulatory support (tMCS) to address issues of deconditioning and sarcopenia. The authors highlight the need for standardized protocols and multidisciplinary collaboration, while noting the lack of high-quality data on the impact of early ambulation on clinical outcomes and functional recovery. They call for further research to establish best practices in tMCS rehabilitation.

Clinical Implications of Resting Metabolic Rate in Heart Failure with Preserved Ejection Fraction

Jul 27, 2026

The authors investigate the role of resting metabolic rate (RMR) in patients with heart failure with preserved ejection fraction (HFpEF) and its clinical implications. They categorize patients based on their RMR and find that those with higher-than-expected RMR exhibit certain hemodynamic adaptations at rest but show impaired cardiovascular reserve during exercise, leading to a higher risk of adverse outcomes. The study highlights the need for further research to understand how RMR influences the pathophysiology of HFpEF and its potential as a therapeutic target.

Screening for features of advanced heart failure with reduced ejection fraction in stable outpatients - The SAINTS study

Jul 23, 2026

The SAINTS study aimed to identify features of advanced heart failure with reduced ejection fraction (HFrEF) in stable outpatients with chronic heart failure and an ejection fraction of ≤30%. The study found that approximately 6% of screened patients exhibited features of advanced HFrEF, while nearly one-third experienced hemodynamic compromise, highlighting the potential for simple clinical markers to enhance screening processes in this population.

Molecular Heterogeneity and Prognostic Implications of Low-Grade Acute Cellular Rejection (1R/1A) in Heart Transplantation

Jul 20, 2026

The authors aimed to investigate the molecular and clinical significance of low-grade acute cellular rejection (ISHLT grade 1R/1A) in heart transplantation, questioning whether this histological finding reflects biologically meaningful alloimmune activation and affects prognostic risk. Their study found that while histologic 1R/1A was not associated with graft dysfunction, it correlated with higher levels of circulating biomarkers and an increased risk of subsequent rejection. Importantly, molecular diagnostics revealed a subset of 1R/1A cases with elevated risk for future rejection, suggesting the need for integrating molecular assessments into post-transplant risk stratification.

Deep learning interpretation of echocardiographic images predicts incident heart failure and subtypes

Jul 15, 2026

The authors aimed to determine whether deep learning analysis of echocardiographic images could improve the prediction of incident heart failure (HF) compared to existing clinical risk models. They developed and validated a model called Echo2HF using a large dataset, demonstrating that it accurately discriminated future HF risk with a 10-year AUROC of 0.83 and 0.82 in two independent cohorts, outperforming traditional risk scores. The findings suggest that integrating artificial intelligence in echocardiography may enhance HF prevention strategies and clinical outcomes.

Unintended Financial Barriers: When "Generic" Does Not Mean Affordable

Jul 14, 2026

The authors investigate the financial barriers that persist for patients prescribed generic sacubitril/valsartan, a key treatment for heart failure with reduced ejection fraction (HFrEF), despite its introduction aimed at improving affordability. They highlight how high deductibles, variable insurance coverage, and administrative hurdles disproportionately impact vulnerable populations, leading to treatment interruptions and financial toxicity. The study calls for aligning healthcare benefit designs with evidence-based practices to ensure that the availability of generics translates into improved access and patient outcomes.

An abbreviated exercise right heart catheterization protocol for the diagnosis of heart failure with preserved ejection fraction

Jul 11, 2026

The authors aimed to determine if a 3-minute abbreviated exercise right heart catheterization (eRHC) protocol could accurately diagnose heart failure with preserved ejection fraction (HFpEF) compared to the standard peak exercise protocol. Their findings demonstrated that the abbreviated protocol had good sensitivity (85%) and specificity (85%) for diagnosing HFpEF, with strong correlations in hemodynamic measurements, suggesting it could enhance the accessibility and efficiency of HFpEF diagnosis without compromising accuracy.

SLEEP-DISORDERED BREATHING IN HEART FAILURE: PHENOTYPES, MECHANISMS, AND PRECISION APPROACH

Jul 10, 2026

The authors investigate the complex relationship between sleep-disordered breathing (SDB) and heart failure (HF), aiming to understand how different phenotypes of SDB affect clinical outcomes and treatment efficacy. They highlight that traditional metrics may not adequately capture cardiovascular risk, suggesting a need for precision-based approaches that consider individual patient characteristics and physiological markers to improve management strategies for SDB in HF. The paper emphasizes the limitations of current treatments and the potential for alternative therapies tailored to specific phenotypes of SDB in heart failure patients.

Heart Failure Pharmacotherapy Across the TAVR Continuum

Jul 4, 2026

The authors investigate the role of guideline-directed medical therapy (GDMT) in managing heart failure across the continuum of transcatheter aortic valve replacement (TAVR) procedures, highlighting the need for optimized pharmacotherapy despite persistent myocardial disease post-TAVR. They emphasize the potential benefits of specific drug classes, particularly renin-angiotensin system inhibitors (RASi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), while identifying key uncertainties regarding timing and patient selection. The review calls for further randomized trials to establish effective implementation strategies for GDMT in TAVR patients.